Lorlatinib

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Anaplastic Large Cell Lymphoma, ALK-Positive

Conditions

Anaplastic Large Cell Lymphoma, ALK-Positive

Trial Timeline

Oct 10, 2017 → Dec 1, 2024

NCT ID

NCT03505554

About Lorlatinib

Lorlatinib is a phase 2 stage product being developed by Pfizer for Anaplastic Large Cell Lymphoma, ALK-Positive. The current trial status is unknown. This product is registered under clinical trial identifier NCT03505554. Target conditions include Anaplastic Large Cell Lymphoma, ALK-Positive.

What happened to similar drugs?

0 of 1 similar drugs in Anaplastic Large Cell Lymphoma, ALK-Positive were approved

Approved (0) Terminated (0) Active (1)

🔄Alectinib + CrizotinibRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03127618	Pre-clinical	Completed	—	—	—
NCT03178071	Pre-clinical	Completed	—	—	Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
NCT06678555	Pre-clinical	Active	Jul 4, 2025	Jun 30, 2026	Carcinoma, Non-Small-Cell Lung
NCT06487078	Pre-clinical	Recruiting	Jan 20, 2025	Nov 30, 2028	ALK+ Non-Small-Cell Lung Carcinoma
NCT05297890	Phase 2	Active	May 27, 2022	May 1, 2026	Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
NCT05224609	Phase 1	Completed	Apr 28, 2022	Aug 13, 2024	Moderate Hepatic Impairment
NCT05144997	Approved	Active	Dec 28, 2021	Dec 28, 2026	Non-Small-Cell Lung Cancer
NCT04753658	Pre-clinical	Terminated	Mar 19, 2021	Sep 30, 2022	Neuroblastoma
NCT04362072	Approved	Completed	Sep 29, 2020	Oct 23, 2024	Carcinoma
NCT04541706	Approved	Completed	Aug 27, 2020	Jul 20, 2022	Advanced Non-Small Cell Lung Cancer
NCT06282991	Pre-clinical	Completed	Jul 22, 2020	Jan 18, 2021	Non-Small Cell Lung Carcinoma
NCT03909971	Phase 2	Completed	Apr 28, 2019	Oct 21, 2024	Carcinoma, Non-Small-Cell Lung
NCT03542305	Phase 1	Completed	Aug 23, 2018	Feb 20, 2020	Renal Impairment
NCT03505554	Phase 2	UNKNOWN	Oct 10, 2017	Dec 1, 2024	Anaplastic Large Cell Lymphoma, ALK-Positive

Competing Products

20 competing products in Anaplastic Large Cell Lymphoma, ALK-Positive

See all competitors

Product	Company	Stage	Hype Score
CS-7017 + Paclitaxel	Daiichi Sankyo	Phase 1/2	24
efatutazone + paclitaxel	Daiichi Sankyo	Phase 2	35
Lenvatinib 24 mg	Eisai	Phase 2	27
Lenvatinib + Nivolumab	Ono Pharmaceutical	Phase 2	39
durvalumab + tremelimumab	AstraZeneca	Phase 1	29
Pembrolizumab	Merck	Phase 2	35
LDK378 + AUY922	Novartis	Phase 1	29
ceritinib	Novartis	Pre-clinical	30
LDK378	Novartis	Phase 1	29
Ceritinib	Novartis	Phase 2	27
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastim	Novartis	Phase 1	29
dabrafenib/trametinib	Novartis	Phase 2	42
Trametinib + Paclitaxel	Novartis	Phase 1	33
Alectinib + Crizotinib	Roche	Phase 3	44
Sunitinib Malate	Pfizer	Phase 2	35
Crizotinib (PF-02341066)	Pfizer	Phase 2	35
Crizotinib	Pfizer	Phase 1/2	32
Cemiplimab + XL092	Regeneron Pharmaceuticals	Phase 1	36
Etirinotecan pegol	Nektar Therapeutics	Phase 2	29
Bevacizumab	Novocure	Phase 2	36